KR20050114214A - 백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도 - Google Patents
백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도 Download PDFInfo
- Publication number
- KR20050114214A KR20050114214A KR1020057014582A KR20057014582A KR20050114214A KR 20050114214 A KR20050114214 A KR 20050114214A KR 1020057014582 A KR1020057014582 A KR 1020057014582A KR 20057014582 A KR20057014582 A KR 20057014582A KR 20050114214 A KR20050114214 A KR 20050114214A
- Authority
- KR
- South Korea
- Prior art keywords
- hsgk1
- gene
- hsgk3
- glaucoma
- cataracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/166—Cataract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/168—Glaucoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10305212A DE10305212A1 (de) | 2003-02-07 | 2003-02-07 | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
| DE10305212.7 | 2003-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050114214A true KR20050114214A (ko) | 2005-12-05 |
Family
ID=32730900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057014582A Withdrawn KR20050114214A (ko) | 2003-02-07 | 2004-02-05 | 백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1663246A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006519189A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050114214A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1771039A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004210416A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0407300A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2514703A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE10305212A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05008394A (cg-RX-API-DMAC7.html) |
| PL (1) | PL378399A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2005127808A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004069258A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200506280B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070191326A1 (en) * | 2004-03-11 | 2007-08-16 | Florian Lang | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases |
| US20070203085A1 (en) * | 2004-03-11 | 2007-08-30 | Florian Lang | Methods For Interfering With Fibrosis |
| DE102004059781A1 (de) * | 2004-12-10 | 2006-06-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung der Serum-/Glucocorticoid regulierten Kinase |
| US20060293378A1 (en) * | 2005-06-28 | 2006-12-28 | Mcintire Gregory | Method of lowering intraocular pressure |
| WO2007037560A1 (ja) * | 2005-09-30 | 2007-04-05 | Link Genomics, Inc. | Sgk2遺伝子の治療的又は診断的用途 |
| AU2006318550A1 (en) * | 2005-11-22 | 2007-05-31 | Mcgill University | Intraocular pressure-regulated early genes and uses thereof |
| WO2008079980A1 (en) * | 2006-12-22 | 2008-07-03 | Alcon Research, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
| DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
| EP2667885B1 (en) * | 2011-01-25 | 2018-08-08 | Monell Chemical Senses Center | Compositions and methods for providing or modulating sweet taste and methods of screening therefor |
| CN119303113A (zh) * | 2024-09-03 | 2025-01-14 | 河北大学附属医院 | Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69535673D1 (de) * | 1994-08-30 | 2008-02-07 | Univ Dundee | Mittel zur induktion von apoptosis und zur therapieanwendung |
| CA2222562A1 (en) * | 1995-06-07 | 1996-12-19 | Jeffrey N. Miner | Method for screening for receptor agonists and antagonists |
| US5925523A (en) * | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| DE19708173A1 (de) * | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
| AU3991499A (en) * | 1998-05-15 | 1999-12-06 | Joslin Diabetes Center | Independent regulation of basal and insulin-stimulated glucose transport |
| WO2000035946A1 (en) * | 1998-12-14 | 2000-06-22 | The University Of Dundee | Methods |
| US6399655B1 (en) * | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
| DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| AU5840300A (en) * | 1999-07-14 | 2001-01-30 | University Of Lausanne | Glutx polypeptide family and nucleic acids encoding same |
| US6416759B1 (en) * | 1999-09-30 | 2002-07-09 | The Regents Of The University Of California | Antiproliferative Sgk reagents and methods |
| US20030236246A1 (en) * | 2002-04-30 | 2003-12-25 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
| DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
-
2003
- 2003-02-07 DE DE10305212A patent/DE10305212A1/de not_active Withdrawn
-
2004
- 2004-02-05 CA CA002514703A patent/CA2514703A1/en not_active Abandoned
- 2004-02-05 CN CNA2004800070348A patent/CN1771039A/zh active Pending
- 2004-02-05 MX MXPA05008394A patent/MXPA05008394A/es unknown
- 2004-02-05 AU AU2004210416A patent/AU2004210416A1/en not_active Abandoned
- 2004-02-05 RU RU2005127808/15A patent/RU2005127808A/ru not_active Application Discontinuation
- 2004-02-05 PL PL378399A patent/PL378399A1/pl not_active Application Discontinuation
- 2004-02-05 BR BR0407300-2A patent/BRPI0407300A/pt not_active IP Right Cessation
- 2004-02-05 EP EP04708350A patent/EP1663246A2/de not_active Withdrawn
- 2004-02-05 WO PCT/EP2004/001048 patent/WO2004069258A2/de not_active Ceased
- 2004-02-05 KR KR1020057014582A patent/KR20050114214A/ko not_active Withdrawn
- 2004-02-05 JP JP2006501737A patent/JP2006519189A/ja active Pending
-
2005
- 2005-08-05 ZA ZA200506280A patent/ZA200506280B/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
| WO2022124564A1 (ko) * | 2020-12-10 | 2022-06-16 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2514703A1 (en) | 2004-08-19 |
| ZA200506280B (en) | 2006-05-31 |
| WO2004069258A3 (de) | 2005-02-24 |
| RU2005127808A (ru) | 2006-05-27 |
| PL378399A1 (pl) | 2006-04-03 |
| WO2004069258A2 (de) | 2004-08-19 |
| DE10305212A1 (de) | 2004-08-19 |
| AU2004210416A1 (en) | 2004-08-19 |
| CN1771039A (zh) | 2006-05-10 |
| MXPA05008394A (es) | 2005-10-05 |
| BRPI0407300A (pt) | 2006-02-07 |
| EP1663246A2 (de) | 2006-06-07 |
| JP2006519189A (ja) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roy et al. | Fibronectin overexpression in retinal microvessels of patients with diabetes. | |
| US7867492B2 (en) | Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies | |
| JP2006514021A (ja) | Janusチロシンキナーゼ3(Jak3)を選択的に阻害するための方法 | |
| Wang et al. | Increased expression of serum amyloid A in glaucoma and its effect on intraocular pressure | |
| JP2006519189A (ja) | 白内障および緑内障を診断および治療するための、sgk遺伝子ファミリーの使用 | |
| US20090029904A1 (en) | Compositions and methods for treatment of insulin-resistance diseases | |
| WO2021173712A1 (en) | Molecular biomarkers and targets for fuchs' endothelial corneal dystrophy and glaucoma | |
| CN100406570C (zh) | 用作诊断和治疗靶标的Sgk和Nedd | |
| CN1193756C (zh) | 用作诊断和治疗靶点的sgk2和sgk3 | |
| JP2004507262A (ja) | 慢性炎症性気道疾病の炎症状態に明瞭な影響を与える物質の同定方法 | |
| JP2019182873A (ja) | 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法 | |
| JP4762552B2 (ja) | 診断用および治療用標的としてのsgk1 | |
| Li et al. | Estrogen receptor 1 activation suppresses microglia-derived Tnf-α signaling as a photoreceptor self-protection mechanism | |
| US20130040298A1 (en) | Two-pore channels as regulators of proliferation in cancer | |
| JP2004516038A (ja) | 慢性炎症性気道疾患の炎症性状態に陽性の影響を与える物質を同定するための方法 | |
| US8372582B2 (en) | Methods of modulating metabolic memory | |
| US20040092475A1 (en) | Organic compounds | |
| US20020160438A1 (en) | Method for identifying compounds which positively influence inflammatory conditions | |
| KR20050016494A (ko) | 진단 및 치료 표적으로 사용되는 sgk 및 nedd | |
| US20030068660A1 (en) | Methods of ameliorating arthritis by modulating JNK signalsome activity | |
| WO2008016118A1 (en) | Agent targeting dopamine receptor and screening method therefor | |
| AU2007211655A1 (en) | Methods for interfering with glucocorticoid induced gastric acid secretion | |
| CN101506234A (zh) | Gprc变异体在帕金森氏病治疗和诊断中的鉴定和使用 | |
| HK1061801B (en) | Sgk2 and sgk3 used as diagnostic and therapeutic targets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050808 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |